IBO (Impact BioMedical) LT-Debt-to-Total-Asset : 0.17 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Impact BioMedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Impact BioMedical's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.17.

Impact BioMedical's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.17). It may suggest that Impact BioMedical is progressively becoming more dependent on debt to grow their business.

Impact BioMedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Impact BioMedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impact BioMedical LT-Debt-to-Total-Asset Chart

Impact BioMedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Impact BioMedical Quarterly Data
	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.17

Impact BioMedical LT-Debt-to-Total-Asset Calculation

Impact BioMedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	44.633
	=

Impact BioMedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	7.971	/	46.695
	=

Impact BioMedical (AMEX:IBO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Impact BioMedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Impact BioMedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Impact BioMedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impact BioMedical Inc (AMEX:IBO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wiregrass Parkway, West Henrietta, NY, USA, 14586

Website

https://www.impactbiomedinc.com

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Impact BioMedical Headlines

From GuruFocus

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

By Marketwired • 09-16-2024